These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34698568)

  • 21. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
    Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
    J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer.
    Komatsu H; Mizuguchi S; Izumi N; Chung K; Hanada S; Inoue H; Suehiro S; Nishiyama N
    World J Surg Oncol; 2013 Dec; 11():309. PubMed ID: 24313932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
    He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
    Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
    Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
    J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.
    Zhang R; Chen C; Dong X; Shen S; Lai L; He J; You D; Lin L; Zhu Y; Huang H; Chen J; Wei L; Chen X; Li Y; Guo Y; Duan W; Liu L; Su L; Shafer A; Fleischer T; Moksnes Bjaanæs M; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
    Chest; 2020 Aug; 158(2):808-819. PubMed ID: 32113923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients 
Treated with Surgery].
    Yang H; Dai L; Li P; Shen L; Yan W; Fan M; Chen K
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):505-11. PubMed ID: 26302348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
    Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
    Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
    J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2?
    Rea F; Marulli G; Callegaro D; Zuin A; Gobbi T; Loy M; Sartori F
    Lung Cancer; 2004 Aug; 45(2):215-20. PubMed ID: 15246193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China.
    Wang RQ; Long XR; Ge CL; Zhang MY; Huang L; Zhou NN; Hu Y; Li RL; Li Z; Chen DN; Zhang LJ; Wen ZS; Mai SJ; Wang HY
    J Transl Med; 2020 Aug; 18(1):320. PubMed ID: 32819367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.
    Wang CL; Li Y; Yue DS; Zhang LM; Zhang ZF; Sun BS
    World J Surg; 2012 Feb; 36(2):455-62. PubMed ID: 22187129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer-aided diagnosis of distal metastasis in non-small cell lung cancer by low-dose CT based radiomics and deep learning signatures.
    Song X; Duan X; He X; Wang Y; Li K; Deng B; Chen X; Wang Y; Li M; Shan H
    Radiol Med; 2024 Feb; 129(2):239-251. PubMed ID: 38214839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study.
    Zhong Y; Cai C; Chen T; Gui H; Chen C; Deng J; Yang M; Yu B; Song Y; Wang T; Chen Y; Shi H; Xie D; Chen C; She Y
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):521-534. PubMed ID: 37725128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.